Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally

Summary

New Alzheimer’s drugs, lecanemab and donanemab, approved in 2024, mark a significant step in dementia treatment by slowing cognitive decline by 30%.

While high costs, advanced diagnostic tools, and intravenous administration limit accessibility, experts anticipate simpler, affordable solutions like blood-based tests and injectable or oral medications in the future.

With 127 Alzheimer’s drugs in trials, treatments may eventually reach underserved regions.

Experts emphasize prevention, noting 40% of dementia cases could be avoided by addressing risk factors like smoking and air pollution.